One of the biggest surprises of 2020 was how biopharma M&A emerged relatively unscathed from Covid-19.
Early 2021 will see rare diseases dominate for biotech, with Sarepta revealing key data on its gene therapy play.
The deal solves several problems for Astra, and ranks as biopharma’s fifth-biggest cross-border transaction.
As Jak inhibition takes a big knock, attention turns to other immunosuppressive mechanisms being studied in very ill Covid-19 patients.
Outside of vaccines and antibodies, few experimental agents have made it into large, robust clinical trials.
Sobi picking up rights to Apellis’s complement factor C3 inhibitor adds to earlier deals focused on C5, D and anti-FcRn antibodies.
Amylyx believes it has found a disease-modifying therapy in AMX0035, as other key readouts approach.
Other groups with large disconnects between sellside and investor expectations include Beigene, Alnylam and Acceleron.